Ifp Advisors, Inc Larimar Therapeutics, Inc. Transaction History
Ifp Advisors, Inc
- $2.91 Billion
- Q4 2024
A detailed history of Ifp Advisors, Inc transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Ifp Advisors, Inc holds 4 shares of LRMR stock, worth $13. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4Holding current value
$13% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LRMR
# of Institutions
125Shares Held
67.1MCall Options Held
505KPut Options Held
76.3K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$69.9 Million2.59% of portfolio
-
Janus Henderson Group PLC London, X06.44MShares$21.2 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$19.9 Million0.55% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.65MShares$15.3 Million7.6% of portfolio
-
Goldman Sachs Group Inc New York, NY4.15MShares$13.7 Million0.0% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $142M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...